The biopharmaceutical corporation ProMetic Life Sciences announced today that it had received an $11.4 million purchase order for the supply of affinity resin from an existing client, a global leader in the biotherapeutics industry. This is the second purchase order resulting from the license and long-term supply agreement previously announced on July 8, 2013. The affinity resin will be manufactured by ProMetic at its Isle of Man facility and supplied to the client throughout the second half
12 Feb 2015
CA$11.4m Purchase Order from Multinational Client
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
CA$11.4m Purchase Order from Multinational Client
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
12 Feb 2015 -
Author:
Derren Nathan -
Pages:
6
The biopharmaceutical corporation ProMetic Life Sciences announced today that it had received an $11.4 million purchase order for the supply of affinity resin from an existing client, a global leader in the biotherapeutics industry. This is the second purchase order resulting from the license and long-term supply agreement previously announced on July 8, 2013. The affinity resin will be manufactured by ProMetic at its Isle of Man facility and supplied to the client throughout the second half